Invention Grant
- Patent Title: Crystalline forms of a JAK inhibitor compound
-
Application No.: US15966452Application Date: 2018-04-30
-
Publication No.: US10251874B2Publication Date: 2019-04-09
- Inventor: Marta Dabros , Venkat R. Thalladi , Jerry Nzerem , Melanie A. Kleinschek , Glenn D. Crater
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: A61K31/4468
- IPC: A61K31/4468 ; A61K9/00 ; A61P27/02 ; A61P11/08 ; A61P11/06

Abstract:
The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. The invention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.
Public/Granted literature
- US20180311223A1 CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND Public/Granted day:2018-11-01
Information query
IPC分类: